Soleno Therapeutics (NASDAQ:SLNO) Downgraded by Piper Sandler to Hold

Piper Sandler cut shares of Soleno Therapeutics (NASDAQ:SLNO) from a strong-buy rating to a hold rating in a research note published on Tuesday morning,Zacks.com reports.

Other research analysts have also recently issued reports about the company. Robert W. Baird cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. TD Cowen cut Soleno Therapeutics from a “buy” rating to a “hold” rating and lowered their price target for the stock from $85.00 to $53.00 in a report on Tuesday. Wall Street Zen cut Soleno Therapeutics from a “buy” rating to a “hold” rating in a report on Sunday, March 22nd. Lifesci Capital cut Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, HC Wainwright lowered their price target on Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, March 4th. Four investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $89.20.

Soleno Therapeutics Stock Up 0.2%

NASDAQ SLNO opened at $52.35 on Tuesday. The stock’s 50 day moving average is $38.17 and its 200 day moving average is $47.80. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. Soleno Therapeutics has a 12 month low of $29.43 and a 12 month high of $90.32. The stock has a market cap of $2.70 billion, a PE ratio of 227.62 and a beta of -2.81.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.16. The business had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. Research analysts predict that Soleno Therapeutics will post -3.72 EPS for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Large investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. increased its stake in Soleno Therapeutics by 52.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 407,444 shares of the company’s stock worth $27,543,000 after acquiring an additional 140,779 shares during the last quarter. Avoro Capital Advisors LLC increased its stake in Soleno Therapeutics by 25.7% in the 3rd quarter. Avoro Capital Advisors LLC now owns 2,577,777 shares of the company’s stock worth $174,258,000 after acquiring an additional 527,777 shares during the last quarter. Schroder Investment Management Group increased its stake in Soleno Therapeutics by 1,554.9% in the 3rd quarter. Schroder Investment Management Group now owns 280,296 shares of the company’s stock worth $19,105,000 after acquiring an additional 263,359 shares during the last quarter. Kingdon Capital Management L.L.C. bought a new stake in Soleno Therapeutics in the 3rd quarter worth approximately $20,348,000. Finally, Capital World Investors increased its stake in Soleno Therapeutics by 34.1% in the 3rd quarter. Capital World Investors now owns 824,514 shares of the company’s stock worth $55,737,000 after acquiring an additional 209,681 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Soleno Therapeutics News Summary

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Neurocrine agreed to acquire Soleno for about $2.9B, offering $53.00 per share in cash (a meaningful premium to recent trade); the deal provides a near‑term liquidity event and floor for shareholder value. Neurocrine to Buy Soleno for $2.9 Billion
• Positive Sentiment: Market commentary and coverage noted the $53/share offer and framed it as a strategic fit for Neurocrine’s rare‑disease/endocrinology push, supporting near‑term upside to the transaction price if the deal closes. Neurocrine Biosciences to acquire Soleno Therapeutics
• Neutral Sentiment: Soleno voluntarily withdrew its European marketing application for its Prader‑Willi treatment as Neurocrine sharpens focus on the U.S. market — a programmatic change that reduces near‑term EU regulatory exposure but removes a potential international revenue opportunity. Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover
• Negative Sentiment: Several sell‑side firms downgraded or cut price targets (Cantor Fitzgerald, Wolfe Research, Lifesci; TD Cowen cut its target to $53 from $85) — analyst caution could pressure sentiment and constrain upside beyond the deal price. Cantor Fitzgerald Downgrades Soleno Therapeutics
• Negative Sentiment: Multiple securities class‑action lawsuits, and a flurry of law‑firm notices seeking lead plaintiffs, allege disclosures issues tied to the DCCR (VYKAT XR) program; several firms are investigating the fairness of the Neurocrine deal and potential fiduciary claims — these legal risks can create deal uncertainty, potential remediation costs, and timeline delays. Soleno Therapeutics, Inc. (SLNO) Class Action Lawsuit
• Negative Sentiment: Investor‑rights and M&A litigation firms have launched investigations into whether Soleno’s board obtained a fair price and whether prior disclosures misstated drug risks — these actions raise the chance of post‑deal litigation or negotiated adjustments. Halper Sadeh investigation into sale price

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.